<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635424</url>
  </required_header>
  <id_info>
    <org_study_id>10790330DOC</org_study_id>
    <nct_id>NCT03635424</nct_id>
  </id_info>
  <brief_title>Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study</brief_title>
  <official_title>Transcatheter Aortic Valve Replacement (TAVR) With Medtronic TAVR System in Patients With Severe Bicuspid Aortic Valve Stenosis and at Low Predicted Risk of Mortality With Surgical Aortic Valve Replacement (SAVR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to evaluate the procedural safety and efficacy of the Medtronic&#xD;
      TAVR system in patients with bicuspid aortic anatomy and severe aortic stenosis at low risk&#xD;
      for SAVR&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, prospective, single arm&#xD;
&#xD;
      All subjects will be treated with a Medtronic TAVR system. Subject follow-ups will be&#xD;
      conducted at pre and post-procedure, discharge, 30 days, 1 year, and annually through 10&#xD;
      years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 30, 2018</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Actual">November 13, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Percent of Participants With All-Cause Mortality or Disabling Stroke Rate at 30 Days Post-procedure.</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of of all-cause mortality or disabling stroke rate at 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Percent of Participants Who Meet All Device Success Criteria at 30 Days Post-procedure.</measure>
    <time_frame>7 days</time_frame>
    <description>Device success rate, defined as:&#xD;
Absence of procedural mortality, AND&#xD;
Correct positioning of a single prosthetic heart valve into the proper anatomical location, AND&#xD;
Absence of moderate or severe total prosthetic valve regurgitation (at 18 hours to 7 days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-Cause Mortality Rate</measure>
    <time_frame>1 year and annually through 10 years</time_frame>
    <description>Rate of all cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Stroke (Disabling and Non-Disabling) Rate</measure>
    <time_frame>1 year and annually through 10 years</time_frame>
    <description>Rate of disabling and non-disabling strokes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With New Permanent Pacemaker Implantation at 30 Days Post-procedure.</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of new permanent pacemaker implantation at 30 days post-procedure (excludes patients with pre-existing pacemaker at baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Who Experience a Myocardial Infarction at 30 Days Post-procedure.</measure>
    <time_frame>30 days</time_frame>
    <description>The rate of myocardial infarction at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With a Life-Threatening Bleeding Event at 30 Days Post-procedure.</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of life-threatening (or disabling) bleeding at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Prosthetic Valve Endocarditis at 30 Days Post-procedure.</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of prosthetic valve endocarditis at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participant With Prosthetic Valve Thrombosis at 30 Days Post-procedure.</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of prosthetic valve thrombosis at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent pf Participants With Valve-Related Dysfunction Requiring Repeat Procedure at 30 Days Post-procedure.</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of valve-related dysfunction requiring repeat procedure at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With a Repeat Hospitalization for Aortic Valve Disease at 30 Days Post-procedure.</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of repeat hospitalization for aortic valve disease at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With a Repeat Hospitalization for Ascending Aorta Disease at 30 Days Post-procedure.</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of repeat hospitalization for ascending aorta disease at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Performance Metrics by Doppler Echocardiography: Mean Aortic Gradient Reported as Mean Average at Baseline and 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>Reporting of prosthetic valve hemodynamic performance by transvalvular mean aortic gradient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Performance Metrics by Doppler Echocardiography: Effective Orifice Area Reported as Mean Average at Baseline and 30 Days.</measure>
    <time_frame>30 days</time_frame>
    <description>Change in hemodynamic performance metrics by Doppler echocardiography measured by effective orifice area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Performance Metrics by Doppler Echocardiography: Percent of Participants With Degrees of Total Prosthetic Valve Regurgitation at Baseline and 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>Reporting of prosthetic valve hemodynamic performance by degree of total prosthetic valve regurgitation at 30 days post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Performance Metrics by Doppler Echocardiography: Percent of Participants With Degrees of Paravalvular Prosthetic Regurgitation at 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>Reporting of prosthetic valve hemodynamic performance by degree of paravalvular regurgitation at 30 days post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Performance Metrics by Doppler Echocardiography: Percent of Participants With Degrees of Transvalvular Prosthetic Regurgitation at 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>Reporting of prosthetic valve hemodynamic performance by degree of transvalvular regurgitation at 30 days post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Functional Classification at Baseline and 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>Reporting of NYHA classification change from baseline to 30 days&#xD;
NYHA Classification criteria:&#xD;
Class I: Subjects with cardiac disease but without resulting limitations of physical activity.&#xD;
Class I: Subjects with cardiac disease resulting in slight limitation of physical activity.&#xD;
Class III: Subjects with cardiac disease resulting in marked limitation of physical activity.&#xD;
Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health-related Quality of Life (QoL) as Assessed by Kansas City Cardiomyopathy (KCCQ) Instrument at Baseline and 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>QoL overall summary (all domains below) and clinical summary (physical function and symptoms only) scores and change in summary scores from baseline using the following measures:&#xD;
• KCCQ: Quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (QoL) as Assessed by European QoL (EQ-5D) at Baseline and 30 Days.</measure>
    <time_frame>30 days</time_frame>
    <description>QoL summary scores and change from baseline using the following measures:&#xD;
• EQ-5D: Measures 5 domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that can be converted to utilities using an algorithm. Utilities range from 0 to 1, with 1 representing perfect health, and 0 corresponding to the worst imaginable health state</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Bicuspid Aortic Valve</condition>
  <arm_group>
    <arm_group_label>Medtronic TAVR Systems</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic TAVR Systems</intervention_name>
    <description>Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems</description>
    <arm_group_label>Medtronic TAVR Systems</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Severe aortic stenosis, defined as follows:&#xD;
&#xD;
               1. For symptomatic patients:&#xD;
&#xD;
                  Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), OR mean&#xD;
                  gradient ≥40 mmHg, OR Maximal aortic valve velocity ≥4.0 m/sec by transthoracic&#xD;
                  echocardiography at rest&#xD;
&#xD;
               2. For asymptomatic patients:&#xD;
&#xD;
             Very severe aortic stenosis with an aortic valve area of ≤1.0 cm2 (or aortic valve&#xD;
             area index of ≤0.6 cm2/m2), AND maximal aortic velocity ≥5.0 m/sec, or mean gradient&#xD;
             ≥60 mmHg by transthoracic echocardiography at rest, OR&#xD;
&#xD;
             Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND a mean&#xD;
             gradient ≥40 mmHg or maximal aortic valve velocity ≥4.0 m/sec by transthoracic&#xD;
             echocardiography at rest, AND an exercise tolerance test that demonstrates a limited&#xD;
             exercise capacity, abnormal BP response, or arrhythmia OR&#xD;
&#xD;
             Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND mean&#xD;
             gradient ≥40 mmHg, or maximal aortic valve velocity ≥4.0 m/sec by transthoracic&#xD;
             echocardiography at rest, AND a left ventricular ejection fraction &lt;50%.&#xD;
&#xD;
          2. Patient is considered low risk for SAVR, where low risk is defined as predicted risk&#xD;
             of mortality for SAVR &lt;3% at 30 days per multidisciplinary local heart team&#xD;
             assessment.&#xD;
&#xD;
          3. Bicuspid aortic valve anatomy (all sub-types) confirmed by MDCT.&#xD;
&#xD;
          4. The subject and the treating physician agree that the subject will return for all&#xD;
             required post-procedure follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any condition considered a contraindication for placement of a bioprosthetic valve&#xD;
             (eg, subject is indicated for mechanical prosthetic valve).&#xD;
&#xD;
          2. Age less than 60 years&#xD;
&#xD;
          3. A known hypersensitivity or contraindication to any of the following that cannot be&#xD;
             adequately pre-medicated:&#xD;
&#xD;
               1. aspirin or heparin (HIT/HITTS) and bivalirudin&#xD;
&#xD;
               2. ticlopidine and clopidogrel&#xD;
&#xD;
               3. Nitinol (titanium or nickel)&#xD;
&#xD;
               4. contrast media&#xD;
&#xD;
          4. Blood dyscrasias as defined: leukopenia (WBC &lt;1000 mm3), thrombocytopenia (platelet&#xD;
             count &lt;50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or&#xD;
             hypercoagulable states.&#xD;
&#xD;
          5. Ongoing sepsis, including active endocarditis.&#xD;
&#xD;
          6. Any percutaneous coronary or peripheral interventional procedure with a bare metal&#xD;
             stent or drug eluting stent performed within 30 days prior to screening committee&#xD;
             approval.&#xD;
&#xD;
          7. Multivessel coronary artery disease with a Syntax score &gt;22 and/or unprotected left&#xD;
             main coronary artery.&#xD;
&#xD;
          8. Symptomatic carotid or vertebral artery disease or successful treatment of carotid&#xD;
             stenosis within 10 weeks of Heart Team assessment.&#xD;
&#xD;
          9. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or&#xD;
             mechanical hemodynamic support.&#xD;
&#xD;
         10. Recent (within 2 months of Heart Team assessment) cerebrovascular accident (CVA) or&#xD;
             transient ischemic attack (TIA).&#xD;
&#xD;
         11. Gastrointestinal (GI) bleeding that would preclude anticoagulation.&#xD;
&#xD;
         12. Subject refuses a blood transfusion.&#xD;
&#xD;
         13. Severe dementia (resulting in either inability to provide informed consent for the&#xD;
             study/procedure, prevents independent lifestyle outside of a chronic care facility, or&#xD;
             will fundamentally complicate rehabilitation from the procedure or compliance with&#xD;
             follow-up visits).&#xD;
&#xD;
         14. Estimated life expectancy of less than 24 months due to associated non-cardiac&#xD;
             co-morbid conditions.&#xD;
&#xD;
         15. Other medical, social, or psychological conditions that in the opinion of the&#xD;
             investigator precludes the subject from appropriate consent or adherence to the&#xD;
             protocol required follow-up exams.&#xD;
&#xD;
         16. Currently participating in an investigational drug or another device study (excluding&#xD;
             registries).&#xD;
&#xD;
         17. Evidence of an acute myocardial infarction ≤30 days before the study procedure due to&#xD;
             unstable coronary artery disease (WHO criteria).&#xD;
&#xD;
         18. Need for emergency surgery for any reason.&#xD;
&#xD;
         19. Subject is pregnant or breast feeding.&#xD;
&#xD;
         20. Subject is legally incompetent, or otherwise vulnerable&#xD;
&#xD;
             Anatomical exclusion criteria:&#xD;
&#xD;
         21. Pre-existing prosthetic heart valve in any position.&#xD;
&#xD;
         22. Severe mitral regurgitation amenable to surgical replacement or repair.&#xD;
&#xD;
         23. Severe tricuspid regurgitation amenable to surgical replacement or repair.&#xD;
&#xD;
         24. Moderate or severe mitral stenosis amenable to surgical replacement or repair.&#xD;
&#xD;
         25. Hypertrophic obstructive cardiomyopathy with left ventricular outflow gradient.&#xD;
&#xD;
         26. Prohibitive left ventricular outflow tract calcification.&#xD;
&#xD;
         27. Sinus of Valsalva diameter unsuitable for placement of the self-expanding&#xD;
             bioprosthesis&#xD;
&#xD;
         28. Aortic annulus diameter of &lt;18 or &gt;30 mm.&#xD;
&#xD;
         29. Significant ascending aortopathy requiring surgical repair&#xD;
&#xD;
         30. Ascending aorta diameter &gt; 4.5 cm&#xD;
&#xD;
             For transfemoral or transaxillary (subclavian) access:&#xD;
&#xD;
         31. Access vessel mean diameter &lt;5.0 mm for Evolut 23R, 26R, or 29R mm TAV, or access&#xD;
             vessel mean diameter &lt;5.5 mm for Evolut 34R mm or Evolut PRO 23R, 26R, 29 R mm TAV.&#xD;
             However, for transaxillary (subclavian) access in patients with a patent LIMA, access&#xD;
             vessel mean diameter &lt;5.5mm for Evolut 23R, 26R, or 29R mm TAV, or access vessel mean&#xD;
             diameter &lt;6.0 mm for the Evolut 34R or Evolut PRO TAV.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Reardon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Methodist Hospital Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Forrest, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Basel Ramlawi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paramount Heart</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abrazo Arizona Heart Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Memorial Hospital La Jolla</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Robles Hospital &amp; Medical Center</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthPark Medical Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Memorial Hospital</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Atlanta Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center - Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OhioHealth Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Pinnacle Harrisburg Campus</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Jack and Jane Hamilton Heart &amp; Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paramount Heart</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <results_first_submitted>October 29, 2020</results_first_submitted>
  <results_first_submitted_qc>November 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 21, 2020</results_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicuspid Aortic Valve Disease</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 31, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT03635424/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT03635424/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Medtronic TAVR Systems</title>
          <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Device not implanted</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Medtronic TAVR Systems</title>
          <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years of age</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.3" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area (BSA)</title>
          <description>Calculated surface area of the human body in m^2</description>
          <units>m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Society of Thoracic Surgeons (STS) Score</title>
          <description>STS score of predicted risk of 30-day mortality</description>
          <units>% risk of mortality</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association (NYHA) Classification</title>
          <description>NYHA Classification:&#xD;
Class I: Subjects with cardiac disease but without resulting limitations of physical activity.&#xD;
Class I: Subjects with cardiac disease resulting in slight limitation of physical activity.&#xD;
Class III: Subjects with cardiac disease resulting in marked limitation of physical activity.&#xD;
Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>NYHA Class I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety: Percent of Participants With All-Cause Mortality or Disabling Stroke Rate at 30 Days Post-procedure.</title>
        <description>Rate of of all-cause mortality or disabling stroke rate at 30 days</description>
        <time_frame>30 days</time_frame>
        <population>Attempted Implant Set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Percent of Participants With All-Cause Mortality or Disabling Stroke Rate at 30 Days Post-procedure.</title>
          <description>Rate of of all-cause mortality or disabling stroke rate at 30 days</description>
          <population>Attempted Implant Set</population>
          <units>Percent of participants (K-M rate)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy: Percent of Participants Who Meet All Device Success Criteria at 30 Days Post-procedure.</title>
        <description>Device success rate, defined as:&#xD;
Absence of procedural mortality, AND&#xD;
Correct positioning of a single prosthetic heart valve into the proper anatomical location, AND&#xD;
Absence of moderate or severe total prosthetic valve regurgitation (at 18 hours to 7 days)</description>
        <time_frame>7 days</time_frame>
        <population>Implanted Set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percent of Participants Who Meet All Device Success Criteria at 30 Days Post-procedure.</title>
          <description>Device success rate, defined as:&#xD;
Absence of procedural mortality, AND&#xD;
Correct positioning of a single prosthetic heart valve into the proper anatomical location, AND&#xD;
Absence of moderate or severe total prosthetic valve regurgitation (at 18 hours to 7 days)</description>
          <population>Implanted Set</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" lower_limit="91.3" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-Cause Mortality Rate</title>
        <description>Rate of all cause mortality</description>
        <time_frame>1 year and annually through 10 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Stroke (Disabling and Non-Disabling) Rate</title>
        <description>Rate of disabling and non-disabling strokes</description>
        <time_frame>1 year and annually through 10 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With New Permanent Pacemaker Implantation at 30 Days Post-procedure.</title>
        <description>Rate of new permanent pacemaker implantation at 30 days post-procedure (excludes patients with pre-existing pacemaker at baseline)</description>
        <time_frame>30 days</time_frame>
        <population>Attempted Implant set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With New Permanent Pacemaker Implantation at 30 Days Post-procedure.</title>
          <description>Rate of new permanent pacemaker implantation at 30 days post-procedure (excludes patients with pre-existing pacemaker at baseline)</description>
          <population>Attempted Implant set</population>
          <units>Percent of participants (K-M rate)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Who Experience a Myocardial Infarction at 30 Days Post-procedure.</title>
        <description>The rate of myocardial infarction at 30 days</description>
        <time_frame>30 days</time_frame>
        <population>Attempted Implant set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Who Experience a Myocardial Infarction at 30 Days Post-procedure.</title>
          <description>The rate of myocardial infarction at 30 days</description>
          <population>Attempted Implant set</population>
          <units>Percent of participants (K-M rate)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peri-procedural myocarial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spontaneous myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With a Life-Threatening Bleeding Event at 30 Days Post-procedure.</title>
        <description>Rate of life-threatening (or disabling) bleeding at 30 days</description>
        <time_frame>30 days</time_frame>
        <population>Attempted Implant set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With a Life-Threatening Bleeding Event at 30 Days Post-procedure.</title>
          <description>Rate of life-threatening (or disabling) bleeding at 30 days</description>
          <population>Attempted Implant set</population>
          <units>Percent of participants (K-M rate)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Prosthetic Valve Endocarditis at 30 Days Post-procedure.</title>
        <description>Rate of prosthetic valve endocarditis at 30 days</description>
        <time_frame>30 days</time_frame>
        <population>Attempted Implant set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Prosthetic Valve Endocarditis at 30 Days Post-procedure.</title>
          <description>Rate of prosthetic valve endocarditis at 30 days</description>
          <population>Attempted Implant set</population>
          <units>Percent of participants (K-M rate)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participant With Prosthetic Valve Thrombosis at 30 Days Post-procedure.</title>
        <description>Rate of prosthetic valve thrombosis at 30 days</description>
        <time_frame>30 days</time_frame>
        <population>Attempted Implant set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participant With Prosthetic Valve Thrombosis at 30 Days Post-procedure.</title>
          <description>Rate of prosthetic valve thrombosis at 30 days</description>
          <population>Attempted Implant set</population>
          <units>Percent of participants (K-M rate)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent pf Participants With Valve-Related Dysfunction Requiring Repeat Procedure at 30 Days Post-procedure.</title>
        <description>Rate of valve-related dysfunction requiring repeat procedure at 30 days</description>
        <time_frame>30 days</time_frame>
        <population>Attempted Implant set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Percent pf Participants With Valve-Related Dysfunction Requiring Repeat Procedure at 30 Days Post-procedure.</title>
          <description>Rate of valve-related dysfunction requiring repeat procedure at 30 days</description>
          <population>Attempted Implant set</population>
          <units>Percent of participants (K-M rate)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With a Repeat Hospitalization for Aortic Valve Disease at 30 Days Post-procedure.</title>
        <description>Rate of repeat hospitalization for aortic valve disease at 30 days</description>
        <time_frame>30 days</time_frame>
        <population>Attempted Implant set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With a Repeat Hospitalization for Aortic Valve Disease at 30 Days Post-procedure.</title>
          <description>Rate of repeat hospitalization for aortic valve disease at 30 days</description>
          <population>Attempted Implant set</population>
          <units>Percent of participants (K-M rate)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With a Repeat Hospitalization for Ascending Aorta Disease at 30 Days Post-procedure.</title>
        <description>Rate of repeat hospitalization for ascending aorta disease at 30 days</description>
        <time_frame>30 days</time_frame>
        <population>Attempted Implant set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With a Repeat Hospitalization for Ascending Aorta Disease at 30 Days Post-procedure.</title>
          <description>Rate of repeat hospitalization for ascending aorta disease at 30 days</description>
          <population>Attempted Implant set</population>
          <units>Percent of participants (K-M rate)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodynamic Performance Metrics by Doppler Echocardiography: Mean Aortic Gradient Reported as Mean Average at Baseline and 30 Days</title>
        <description>Reporting of prosthetic valve hemodynamic performance by transvalvular mean aortic gradient</description>
        <time_frame>30 days</time_frame>
        <population>Implanted set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Performance Metrics by Doppler Echocardiography: Mean Aortic Gradient Reported as Mean Average at Baseline and 30 Days</title>
          <description>Reporting of prosthetic valve hemodynamic performance by transvalvular mean aortic gradient</description>
          <population>Implanted set</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.01" spread="16.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.58" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodynamic Performance Metrics by Doppler Echocardiography: Effective Orifice Area Reported as Mean Average at Baseline and 30 Days.</title>
        <description>Change in hemodynamic performance metrics by Doppler echocardiography measured by effective orifice area.</description>
        <time_frame>30 days</time_frame>
        <population>Implanted set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Performance Metrics by Doppler Echocardiography: Effective Orifice Area Reported as Mean Average at Baseline and 30 Days.</title>
          <description>Change in hemodynamic performance metrics by Doppler echocardiography measured by effective orifice area.</description>
          <population>Implanted set</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodynamic Performance Metrics by Doppler Echocardiography: Percent of Participants With Degrees of Total Prosthetic Valve Regurgitation at Baseline and 30 Days</title>
        <description>Reporting of prosthetic valve hemodynamic performance by degree of total prosthetic valve regurgitation at 30 days post-procedure</description>
        <time_frame>30 days</time_frame>
        <population>Implanted set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Performance Metrics by Doppler Echocardiography: Percent of Participants With Degrees of Total Prosthetic Valve Regurgitation at Baseline and 30 Days</title>
          <description>Reporting of prosthetic valve hemodynamic performance by degree of total prosthetic valve regurgitation at 30 days post-procedure</description>
          <population>Implanted set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Trace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mild/Mild to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Moderate/Moderate to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: &gt;=Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: Trace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: Mild/Mild to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: Moderate/Moderate to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: &gt;=Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodynamic Performance Metrics by Doppler Echocardiography: Percent of Participants With Degrees of Paravalvular Prosthetic Regurgitation at 30 Days</title>
        <description>Reporting of prosthetic valve hemodynamic performance by degree of paravalvular regurgitation at 30 days post-procedure</description>
        <time_frame>30 days</time_frame>
        <population>Implanted set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Performance Metrics by Doppler Echocardiography: Percent of Participants With Degrees of Paravalvular Prosthetic Regurgitation at 30 Days</title>
          <description>Reporting of prosthetic valve hemodynamic performance by degree of paravalvular regurgitation at 30 days post-procedure</description>
          <population>Implanted set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 Day: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: Trace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: Mild/Mild to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: Moderate/Moderate to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: &gt;=Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodynamic Performance Metrics by Doppler Echocardiography: Percent of Participants With Degrees of Transvalvular Prosthetic Regurgitation at 30 Days</title>
        <description>Reporting of prosthetic valve hemodynamic performance by degree of transvalvular regurgitation at 30 days post-procedure</description>
        <time_frame>30 days</time_frame>
        <population>Implanted set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Performance Metrics by Doppler Echocardiography: Percent of Participants With Degrees of Transvalvular Prosthetic Regurgitation at 30 Days</title>
          <description>Reporting of prosthetic valve hemodynamic performance by degree of transvalvular regurgitation at 30 days post-procedure</description>
          <population>Implanted set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 Day: None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: Trace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: Mild/Mild to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: Moderate/Moderate to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day: &gt;=Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New York Heart Association (NYHA) Functional Classification at Baseline and 30 Days</title>
        <description>Reporting of NYHA classification change from baseline to 30 days&#xD;
NYHA Classification criteria:&#xD;
Class I: Subjects with cardiac disease but without resulting limitations of physical activity.&#xD;
Class I: Subjects with cardiac disease resulting in slight limitation of physical activity.&#xD;
Class III: Subjects with cardiac disease resulting in marked limitation of physical activity.&#xD;
Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort.</description>
        <time_frame>30 days</time_frame>
        <population>Attempted Implant set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>New York Heart Association (NYHA) Functional Classification at Baseline and 30 Days</title>
          <description>Reporting of NYHA classification change from baseline to 30 days&#xD;
NYHA Classification criteria:&#xD;
Class I: Subjects with cardiac disease but without resulting limitations of physical activity.&#xD;
Class I: Subjects with cardiac disease resulting in slight limitation of physical activity.&#xD;
Class III: Subjects with cardiac disease resulting in marked limitation of physical activity.&#xD;
Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort.</description>
          <population>Attempted Implant set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 day - Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 day - No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 day - Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 day - Died</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Health-related Quality of Life (QoL) as Assessed by Kansas City Cardiomyopathy (KCCQ) Instrument at Baseline and 30 Days</title>
        <description>QoL overall summary (all domains below) and clinical summary (physical function and symptoms only) scores and change in summary scores from baseline using the following measures:&#xD;
• KCCQ: Quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
        <time_frame>30 days</time_frame>
        <population>Attempted Implant set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Health-related Quality of Life (QoL) as Assessed by Kansas City Cardiomyopathy (KCCQ) Instrument at Baseline and 30 Days</title>
          <description>QoL overall summary (all domains below) and clinical summary (physical function and symptoms only) scores and change in summary scores from baseline using the following measures:&#xD;
• KCCQ: Quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
          <population>Attempted Implant set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline KCCQ - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline KCCQ - Clinical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 day KCCQ - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.3" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 day KCCQ - Clinical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 day change from baseline KCCQ - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 day change from baseline KCCQ - Clinical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (QoL) as Assessed by European QoL (EQ-5D) at Baseline and 30 Days.</title>
        <description>QoL summary scores and change from baseline using the following measures:&#xD;
• EQ-5D: Measures 5 domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that can be converted to utilities using an algorithm. Utilities range from 0 to 1, with 1 representing perfect health, and 0 corresponding to the worst imaginable health state</description>
        <time_frame>30 days</time_frame>
        <population>Attempted Implant set</population>
        <group_list>
          <group group_id="O1">
            <title>Medtronic TAVR Systems</title>
            <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (QoL) as Assessed by European QoL (EQ-5D) at Baseline and 30 Days.</title>
          <description>QoL summary scores and change from baseline using the following measures:&#xD;
• EQ-5D: Measures 5 domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that can be converted to utilities using an algorithm. Utilities range from 0 to 1, with 1 representing perfect health, and 0 corresponding to the worst imaginable health state</description>
          <population>Attempted Implant set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline EQ-5D Index Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 day EQ-5D Index Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 day change from baseline EQ-5D Index Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected from study enrollment through the 2 year follow-up visit. Adverse event data are currently available and reported for up to 30 days post-procedure.</time_frame>
      <desc>All new or worsening AEs will be collected through 2 years. After 2 years only serious and device-related events will be collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Medtronic TAVR Systems</title>
          <description>Treatment with Medtronic Evolut PRO and Evolut R systems</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Heparin-Induced Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Complete</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Second Degree</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Bundle Branch Block Left</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Bundle Branch Block Right</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Conduction Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Pulseless Electrical Activity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hemangioma Congenital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal Artery Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Device Embolization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia Klebsiella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Device Deployment Issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Vascular Access Site Complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Embolic Stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Leakage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Device Malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Femoral Artery Dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular Block First Degree</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Bundle Branch Block Left</sub_title>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Bundle Branch Block Right</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anemia Postoperative</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Within 60 days of receipt Medtronic (MDT) will verify presence of Confidential Information (CI) &amp; won't censor or interfere with presentation/conclusions except to protect CI (other than Study Data) &amp; its rights in patentable or copyrightable materials, &amp; check technical accuracy of MDT data. If told by MDT that Publication contains CI or technical errors of MDT data, PI will make requested changes before publishing/presenting. PI will delay publication up to 90 more days, if requested.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hatice Bilgic Lim, PhD; Principal Clinical Research Specialist</name_or_title>
      <organization>Medtronic Coronary and Structural Heart Clinical</organization>
      <phone>763-526-1018</phone>
      <email>hatice.bilgic.lim@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

